Biology Atlas

Map / Concepts

concept · intermediate · partly written

Lymphodepletion: clearing space before cells are infused

Lymphodepletion is chemotherapy given days before an engineered cell infusion to reduce the patient own lymphocytes, which in the studies read improved expansion and persistence of the infused cells.

Also called: lymphodepleting chemotherapy, conditioning

Lymphodepletion in brief

Before CAR T cells are infused, the patient gets chemotherapy that lowers their own white cells. It is part of the treatment: the regimen changes how well the infused cells expand and how long they last. 12

Reported, not yet replicated

Evidence it matters more

In a study of 32 adults with lymphoma, adding fludarabine to cyclophosphamide gave more expansion and persistence of CAR T cells and 50% complete remission against 8% with cyclophosphamide alone (abstract only). Another study linked a stronger response to lymphodepletion with longer progression-free survival (abstract only). The textbook reason, freeing cytokines such as IL-7 and IL-15, was not stated in the sources opened and is unverified. 12

Reported, not yet replicated

A possible cost of the regimen more

The JCAR015 ROCKET trial was stopped after cerebral oedema deaths, and an exploratory analysis reported through trade press linked the heavier fludarabine plus cyclophosphamide cohort to more toxicity. See drugs/jcar015 for the sources and their limits. 1

Our inference

Plain answer

Lymphodepletion is a short chemotherapy course before infusion that clears space for infused cells; in the studies read it changed how many cells expanded and how long they persisted, so the regimen is part of the drug. 12

Reported, not yet replicated

Why it matters

It answers part of the question of how infused cells are made to stay. For CAR T it is about expansion, not about stopping rejection of the patient own cells; for donor cells conditioning and immunosuppression also address rejection. 12

Reported, not yet replicated

Real numbers

Cy/Flu versus Cy

In 32 adults with lymphoma, 50% complete remission with fludarabine plus cyclophosphamide against 8% with cyclophosphamide alone. 1

Reported, not yet replicated

Teach this

In one sentence

Chemotherapy first, so the infused engineered cells have room to multiply. 1

Reported, not yet replicated

The five-minute version

Without it the infused T cells compete with the patient own lymphocytes and may be limited by immune responses to the mouse-derived binder. Adding fludarabine to cyclophosphamide improved expansion and persistence in one study. The regimen is also linked to toxicity. 1

Reported, not yet replicated

What a listener will ask

Is it to prevent rejection?

For CAR T made from the patient own cells, the sources point to expansion, not rejection.

Is it risk free?

No; the chemotherapy has its own toxicity.

Does cell therapy with donor cells need it?

Donor cells also face rejection; see concepts/graft-rejection-and-immunosuppression.

The common wrong idea

The chemotherapy before CAR T is only there to kill cancer.

It is chosen to help the infused cells expand and persist; the regimen changed outcomes in the studies read.

The one citation to hand over: 1

Still open here

Not yet written: Equation.

Linked from

Sources

  1. Turtle, C. J., et al.. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Science Translational Medicine (2016). paper; opened 2026-11-17 all records citing this
  2. Hirayama, A. V., et al.. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood (2019). paper; opened 2026-11-17 all records citing this
History of this record (1)

This record has been changed 1 time, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.

Status
partly written
Last updated
2026-11-17
Record
content/concepts/lymphodepletion.json